MGMT and glioblastoma: suggested that no apparent clinical benefit of continuing TMZ treatment for more than 6 cycles was appeared (9); the results of clinical trial GEINO 14-01 indicated that 12 cycles of TMZ treatment did not confer additional clinical benefits for OS and PFS, even in GBM patients with O (6)-methylguanine DNA methyltransferase (MGMT) promoter methylation (10).